Law firm Hagens Berman is representing Catalent investors in a securities fraud class action, urging those who suffered substantial losses to contact the firm’s attorneys. However, the company has also welcomed prominent Biopharma Leaders to its board, seen as a strategic growth move. Moreover, Novo Holdings has finalized the acquisition of Catalent for $16.5 billion, a deal that has been approved by the European Commission. This development comes after Catalent agreed to sell its Somerset, NJ Oral Solids Facility. The company also issued an open letter to its customers regarding the pending acquisition, indicating a significant transformation. Meanwhile, Catalent missed Q1 revenue estimates, shortly before the closing deal with Novo Holdings. Furthermore, the company also completed a $25 million expansion of its clinical supply facility in Schorndorf, Germany. Concerns arose when US FTC requested more information on the Novo Nordisk parent-Catalent deal. Amid this, Catalent's stock soared to a 52-week high, achieving $62.51. The developments have not been without setbacks, which include a delay in the filing of the annual report, investigation by Pomerantz Law Firm, and layoffs at the Wegovy packing supplier. To offset some of the issues, the company is considering the acquisition of gummies manufacturer Bettera for $1 billion.
Catalent CTLT News Analytics from Mon, 03 Feb 2020 08:00:00 GMT to Mon, 03 Mar 2025 19:51:18 GMT - Rating 6 - Innovation -3 - Information 8 - Rumor -5
